Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A*STAR and GE Global Research Sign Memorandum of Understanding

Published: Friday, April 13, 2012
Last Updated: Friday, April 13, 2012
Bookmark and Share
Agreement to develop integrated advanced medical imaging technologies for improved clinical diagnosis.

GE Global Research, the central technology development arm for GE Healthcare and all of GE's businesses, has signed a Memorandum of Understanding (MOU) with Singapore's Agency of Science, Technology and Research (A*STAR).

This agreement will focus on advancing current medical imaging technologies and diagnostics to enable more accurate, earlier and faster clinical diagnoses of cancer and other diseases.

The partnership between A*STAR and GE Global Research brings together two world-class research institutions, integrating their deep domain expertise in biomedical, science, and engineering capabilities to support this effort.

This MOU expands upon a productive collaboration between GE and A*STAR's Singapore Bioimaging Consortium (SBIC) using Hyperpolarized Carbon-13 technology.

Early results exploring sub second bio-chemical imaging in Oncology applications helped pave the way for a broader scientific collaboration on projects in medical diagnostics and medical imaging.

The goal is to improve diagnosis and tissue characterization in diseases that are prevalent in the Asian population, such as liver, lung, and gastric cancers.

Michael Idelchik, Vice President of Advanced Technology Programs at GE Global Research, said, "To more effectively combat cancer and other deadly diseases, more advanced diagnostic tools will be needed to help doctors become more prescriptive in their diagnoses and treatment regimens. Combining A*STAR's world-class biomedical and clinical expertise with GE's strengths in diagnostic and molecular imaging, we have an exciting opportunity to take medical diagnosis to this next level. Specifically, A*STAR will help us address cancers and other diseases more common in Asia and where pathology and outcomes are different as compared to the rest of the world."

Professor Low Teck Seng, Managing Director of A*STAR, said, "This win-win public-private partnership between A*STAR and GE comes at an opportune time with the increasing research interest in diseases affecting the Asian population. I am confident that A*STAR's cross-disciplinary capabilities in both the biomedical, and physical sciences & engineering research will complement GE's expertise in diagnostic and molecular imaging to meet today's complex healthcare challenges and enhance lives."

As part of the MOU, A*STAR and GE Global Research will collaborate to enhance medical imaging technologies in imaging modalities, ranging from magnetic resonance imaging (MRI) and positron emission tomography (PET) to computed tomography (CT).

In a Frost & Sullivan global market analysis report, the medical imaging sector was valued at about US$25 billion as of 2008, with MRI and CT scanners accounting for a combined 40% of the total global device medical imaging market.

In one project, scientists from A*STAR's Institute of Microelectronics (IME) and GE scientists will explore the development of new imaging technologies to improve the speed and accuracy of clinical cancer diagnosis.

Leveraging IME's network and partnerships with the microelectronics industry, this project could result in the development of a new local industry for Singapore in the healthcare technologies area.

In another project, A*STAR's Singapore Bioimaging Consortium (SBIC) and GE plan to develop novel imaging markers for hepatic cellular carcinoma (HCC), the most common type of liver cancer in Asia.

This project will integrate biomedical imaging and pre-clinical model development expertise from SBIC with GE's molecular diagnostics technology to develop innovative, proprietary platforms to help advance the unique characterization of HCC in each patient.

In this manner, the goal is that a specific type of cancer would be identified and the therapy tailored to each patient. This project encompasses a range of medical diagnostic technologies from imaging to molecular pathology biomarkers appropriate to HCC, relevant to the Asian population.

Building on a close partnership with local hospitals, success in this project may lead to accelerated and accurate cancer diagnosis that enables more prescriptive and effective cancer treatments for patients. This will support A*STAR's efforts to develop Singapore as a Center for Oncology and Molecular Pathology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

A*STAR Scientists Discover Gene Critical for Proper Brain Development
This gene accounts for the size of the human brain and potentially our superior cognitive abilities.
Friday, December 26, 2014
Gene Associated with an Aggressive Breast Cancer Identified
Over-expressed gene in triple negative breast cancer offers new diagnostics for risk assessment.
Wednesday, December 03, 2014
Novel Gene Predicts Both Breast Cancer Relapse and Response to Chemotherapy
A predictive marker discovered by scientists at A*STAR and NUS could help doctors classify breast cancer patients for more effective treatment.
Thursday, August 21, 2014
New Tool to Study Critical Protein Interaction in Cancer Research
A*STAR scientists used fluorescent molecular rotors to study protein-protein interactions involving p53 and MDM2 in cells.
Thursday, July 03, 2014
New Possibilities for Leukaemia Therapy with a Novel Mode of Cancer Cell Recognition
A new class of lipids in human leukaemia cells trigger an immune response to kill the cells.
Thursday, June 26, 2014
Nature and Nurture: Baby's Development is Affected by Genes and Conditions in the Womb
First attempt to discover how genetic and environmental factors affect the human epigenome.
Tuesday, April 29, 2014
Elephant Shark Genome Provides New Insights into Bone Formation in Humans
A*STAR-led international consortium completely decodes the first shark-family member genome.
Thursday, January 09, 2014
A*STAR Scientists Discover Novel Hormone Essential for Heart Development
This unusual discovery could aid cardiac repair and provide new therapies to common heart diseases and hypertension.
Friday, December 06, 2013
A*STAR and NUS Launch Joint Centre
The S$148 million centre will study the role of nutrition and early development in health and disease in Asia.
Thursday, October 10, 2013
Scientists Find a Promising Way To Boost The Body’s Immune Surveillance Via p53
Researchers at A*STAR have discovered a new mechanism involving p53, the famous tumour suppressor, to fight against aggressive cancers.
Thursday, September 26, 2013
Singapore Scientists Discover New RNA Processing Pathway Important in hESCs
Discovery of RNA regulator could lead to a better understanding of diseases like cancer and influenza.
Monday, September 09, 2013
Scientists at GIS Discover Gene that Controls the Birth of Neurons
Discovery of long non-coding RNA's role in neurogenesis may lead to cures for diseases such as Alzheimer's disease.
Thursday, August 29, 2013
A*STAR Scientist Alex Matter Awarded Prestigious Szent-Gyorgyi Prize For Progress In Cancer Research
National Foundation for Cancer Research honours Professor Alex Matter with esteemed award for groundbreaking cancer pill that gives leukaemia patients a new lease of life.
Friday, April 05, 2013
A*STAR Scientists Make Discovery of Cell Nucleus Structure Crucial to Understanding Diseases
Genes relocated from their correct position in the nucleus cause them to malfunction and this may lead to the heart, blood vessels and muscles breaking down.
Friday, February 08, 2013
A*STAR's GIS Collaborates with GSK to Further Research on Lung Cancer
Partnership will advance both organizations' joint efforts towards finding a cure for the disease.
Thursday, January 31, 2013
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!